3-year open-label extension of two phase 3 PsA trials: bimekizumab responses were sustained, with ACR50 in 53.2% of bDMARD-naive and 55.2% of TNFi-IR patients at year 3 (546 and 299 completed), and no new safety signals.
RCT
Gossec et al. Bimekizumab safety and efficacy in patients with psoriatic arthritis: 3-year results from two phase 3 studies